NASDAQ OMX

BroadSoft Named to the Constellation ShortList(TM) for Enterprise Group Messaging

9.8.2017 15:00 | NASDAQ OMX

Del

BroadSoft Business UC-One® App Honored as One of Seven Enterprise Group Messaging Solutions

GAITHERSBURG, Md., Aug.  09, 2017  (GLOBE NEWSWIRE) -- BroadSoft, Inc. (NASDAQ:BSFT), a global market leader in cloud business software for cloud PBX, unified communication, and provider of team collaboration and contact center as a service (CCaaS), today announced that BroadSoft Business UC-One ® application is included in the Constellation ShortList(TM) for enterprise group messaging solutions in Q3 2017. The Constellation ShortList(TM) presents vendors in different categories of the market relevant to early adopters. Inclusion signifies BroadSoft as a leading provider of messaging tools in the market and its influence on the way people expect to be able to communicate at work.

"We are pleased that the UC-One application has been identified by Constellation as a leader in the enterprise messaging industry yet again," said Taher Behbehani, chief digital and marketing officer, BroadSoft. "As the future of work continues to advance, we believe that our BroadSoft Business portfolio of cloud communications and team collaboration solutions will continue to unlock greater productivity for our customers as their employees connect, communicate and collaborate across channels."

Constellation advises leaders and teams on leveraging disruptive technologies to achieve business model transformation. Products and services named to the Constellation ShortList meet the threshold criteria for this category as determined by Constellation Research through client inquiries, partner conversations, customer references, vendor selection projects, market share and internal research.  The Constellation ShortList is frequently updated as market conditions change.

"The right timing, teams and technology are the three Ts for crafting digital business models to achieve digital transformation success," said R "Ray" Wang, chairman and founder at Constellation Research. "Each Constellation ShortList, researched and curated by our analysts, guides early adopters in identifying the right technologies to build successful and competitive programs."

UC-One is an application from the BroadSoft Business portfolio that provides integrated business phone services, messaging and presence, audio and video conferencing, screen sharing, file sharing, virtual meeting rooms and more. The solution provides advanced mobile-first cloud unified communication for businesses of all sizes. Users can communicate and collaborate with colleagues, partners, and customers regardless of location or device. BroadSoft Business is a fully integrated portfolio of enterprise-ready cloud unified communications, team collaboration and contact center applications, delivered in the cloud.

Find out more about BroadSoft UC-One, unified communication and team collaboration solution here.

About BroadSoft

BroadSoft is the technology innovator in cloud PBX, unified communications, team collaboration, and contact center solutions for businesses and service providers across 80 countries. We are the market share leader for cloud unified communications with an open, mobile and secure platform trusted by 25 of the world's top 30 service providers by revenue. Our BroadSoft Business application suite empowers users and teams to share ideas and work simply to achieve breakthrough performance. For additional information, visit www.BroadSoft.com.

Twitter | LinkedIn | BroadSoft Blog

Disclaimer
Constellation Research does not endorse any solution or service named in its research.

About Constellation Research
Constellation Research is an award-winning, Silicon Valley-based strategic advisory and futurist research firm. Constellation's analysts serve as innovation advisors for leaders and Global 2000 organizations navigating the challenges of business-model disruption and transformation. Unlike legacy analyst firms, Constellation works closely with solution providers, partners, and its Constellation Executive Network of innovative buy-side leaders, C-suite executives and board of directors to lead the way in disrupting technology and research coverage areas. The goal - deliver to clients what they need to achieve valuable business results.

For more information about Constellation Research, visit www.ConstellationR.com.

Matter for BroadSoft
Erin Knapp
Matter
617-502-6546
broadsoft@matternow.com

BroadSoft
Niaobh (Neve) Levestam
BroadSoft
+44 7919 605660
nlevestam@broadsoft.com

Constellation Research
Aubrey Coggins
Press@Constellationr.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: BroadSoft, Inc. via Globenewswire

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

Nasdaq Welcomes I-AM Capital Acquisition Company (Nasdaq: IAMXU) to The Nasdaq Stock Market17.8.2017 18:50Pressemelding

NEW YORK, Aug. 17, 2017 (GLOBE NEWSWIRE) -- I-AM Capital Acquisition Company (Nasdaq:IAMXU), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, celebrated its initial public offering (IPO) on The Nasdaq Stock Market.  I-AM Capital's founders, Chief Executive Officer F. Jacob Cherian and Chief Financial Officer Suhel Kanuga, have been focused on investing into India over the last decade, with the distinction of completing the first listed-SPAC investment in India. "Through our keen focus and unique accomplishments in India over the last decade, we have seen our investment thesis bear fruit: India's prominence and rise on the world stage, its distinction as being one of the fastest growing major economies of the world, and its strong vibrant consumer demographics. We believe these factors are aligning well now,

Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency17.8.2017 14:30Pressemelding

WATERTOWN, Mass., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug- resistant (MDR) infections, today announced that the Marketing Authorization Application (MAA) for IV eravacycline for the treatment of complicated intra-abdominal infections (cIAI) has been submitted and was validated by the European Medicines Agency (EMA). Eravacycline is a novel, fully-synthetic fluorocycline antibiotic being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. The MAA filing is based on data from the phase 3 IGNITE1 clinical trial in which eravacycline was well tolerated and demonstrated statistical non-inferiority to ertapenem using the primary endpoint of clinical response at the test-of-cure (TOC) visit. "The MAA filing represents a significant milestone for Tetraphase as it is our

RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules17.8.2017 13:00Pressemelding

RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories Esomeprazole Strontium DR Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI), indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal (GI) conditions   RedHill expects to initiate the U.S. promotion of Esomeprazole Strontium  DR Capsules 49.3 mg  in the coming weeks   Esomeprazole Strontium  DR Capsules 49.3 mg  will be the third commercial GI product to be promoted by RedHill in the U.S.    RedHill's GI-focused sales force currently promotes two GI s

Brand Industrial Services Announces Agreement to Acquire Venko Groep BV16.8.2017 19:40Pressemelding

Complementary core strengths provide broader range of services for customers KENNESAW, GA, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Brand Industrial Services, known as BrandSafway, has signed an agreement to acquire Venko Groep BV, a portfolio company of Mentha Capital. Venko will become a part of the Brand Energy & Infrastructure Services (Brand) group. "We are very pleased to announce the agreement with Venko," said Bill Hayes, President and CEO of BrandSafway. "Our combined customers in Europe will benefit from a broader range of solutions and greater depth of expertise in access, insulation and coatings. Bringing Venko's highly specialized knowledge in coatings to BrandSafway will provide the expertise we need to expand our services in the offshore market worldwide." Based in the Netherlands, with a focus on operations in the North Sea area, Venko is a leading offshore and onshore coatings maintenance provid

Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A16.8.2017 15:38Pressemelding

NEW YORK and CLEVELAND, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, today announced the pivotal expansion of its gene therapy clinical trials for patients with MPS IIIA in the USA, Europe and Australia. "We have completed the necessary regulatory and ethical committee approvals and site initiations in Europe and Australia in order to accelerate enrollment," stated Juan Ruiz, M.D., Ph.D., Abeona's Chief Medical Officer. "We remain very encouraged by the improvements observed in clinically relevant biomarkers post-dosing of ABO-102, including durable reductions in heparan sulfate measured in the CNS, reduction of organ disease pathology, and signals of CNS improvement or stabilization at one-year follow-up in Cohort 1 subjects, and look forward to providing a more fulsome clinical update at important clinical

CallidusCloud Wins Eight Gold Stevies® in the 2017 International Business Awards16.8.2017 14:00Pressemelding

CallidusCloud Lead to Money suite recognized as Best B2B New Product of the Year. LeadRocket voted Best New Product or Service of the Year in the Software - Lead Generation Solution category. DUBLIN, Calif., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Callidus Software Inc. (NASDAQ:CALD), a global leader in cloud-based sales, marketing, learning, and customer experience solutions, announced today that it was named the winner of eight Gold Stevie® awards in the 2017 International Business Awards. "The eight Stevie® awards earned highlight CallidusCloud's momentum, commitment to excellence, passion for innovation and customer orientation," said Leslie Stretch, president and CEO of CallidusCloud. "They also recognize the benefits that the Lead to Money suite, honored as the Best New Product in Business-to-Business, accrues to its customers in terms of enabling faster, bigger, and more profitable sales." CallidusCloud's Go

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom